TBI-2002

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTBI-2002

Drug Alias Nameanti-CEA-GITR-CAR T-Cell therapy (Takara Bio)anti-CEA CAR T-cell therapy (Takara Bio)CEA.GITR.CARTBI-2002

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 modulators

TargetsCarcinoembryonic antigen related cell adhesion molecule 5

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusDiscontinued (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesTakara Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTakara Bio Inc

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A